QMENTA, a leader in neuroimaging AI dedicated to advancing clinical trials and drug development, has appointed Dr. Montserrat Barceló as a strategic advisor. This addition to the advisory board brings over thirty years of extensive clinical research leadership and a robust network within the pharmaceutical industry.
Dr. Barceló’s professional journey includes a significant tenure at TFS HealthScience in Sweden, where she served as global COO. In this role, she oversaw the delivery of clinical trials for over 200 clients and managed a team of more than 750 professionals across 25 global locations. Her experience also includes a directorship in international business operations and M&A integration at Veristat in Boston.
In addition to her operational expertise, Dr. Barceló is a board member of KYMOS and provides advisory services to the U.K.-based trial technology firm Trial Hub. She is also an advisor and investor at IKI Health, a company that leverages AI technology within the longevity and digital health sectors.
Dr. Barceló is a co-founder of WeRock Capital, a women-led angel investment group, and has served as vice president of EjeCon, the Spanish Association of Women Executives and Board Members. This network plays a vital role in promoting gender diversity among senior executives across Europe, aligning with QMENTA’s commitment to inclusive leadership.
Vesna Prchkovska, CEO of QMENTA, remarked on Dr. Barceló’s appointment, stating, “Montse understands how this industry operates—how sponsors evaluate vendors and the nuances of procurement decisions. Her insights will be invaluable in establishing QMENTA as a trusted partner in complex clinical programmes. This level of commercial expertise is rare and timely as we advance our growth strategy.”
Dr. Barceló expressed her enthusiasm for joining QMENTA, noting, “Having spent my career on the other side of the table, I recognise the significance of what QMENTA has achieved in neuroimaging AI. With the increasing importance of biomarkers and the longevity economy, I believe our collaboration is well-timed. Barcelona is experiencing a significant moment in biotech, and I am committed to ensuring QMENTA gains visibility in both the US and Asia. This is an enterprise worth investing in.”
In her new advisory capacity, Dr. Barceló will collaborate closely with Prchkovska and the QMENTA leadership team on growth strategies, enterprise positioning, governance, and international expansion, with a focus on the European and Asia-Pacific markets.
Explore QMENTA’s Imaging Hub by visiting QMENTA.com.
About QMENTA
QMENTA is at the forefront of neuroimaging AI, facilitating biopharma, CROs, and academic research institutions in streamlining intricate imaging clinical trials. The company’s cloud-native Imaging Hub consolidates data management, AI biomarker analysis, and central review into a single compliant system. This integration alleviates site burden and expedites imaging-driven decision-making. Among QMENTA’s clientele are notable organisations such as Amylyx Pharmaceuticals, Alzamend Neuro, Cedars-Sinai, and Cleveland Clinic.